Inventor
GLENN DRANOFF
Inventor
US
Overview
Patents· 7 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Kprimary
A61KPreparations for medical, dental or toiletry purposes26%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations22%
C07KPeptides19%
C12NMicroorganisms or enzymes19%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms7%
G01NInvestigating or analysing materials by determining their chemical or physical properties4%
Y02ATechnologies for adaptation to climate change4%
PatentTitleYear
12,383,601Chimeric antigen receptors and uses thereof202512,037,583Compositions and methods for immunooncology202411,998,593Combination vaccine devices and methods of killing cancer cells202411,851,472NKG2D-IG fusion protein for cancer immunotherapy202311,624,093Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response202311,597,934Methods and compositions for reducing immunosuppression by tumor cells202311,382,905Immunomodulation by IAP inhibitors2022Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2022–2024Patents assigned to DANA FARBER CANCER INST INC (5)· patent assignee history
2022–2025Patents assigned to NOVARTIS AG (3)· patent assignee history
2022–2025Based in US· patent location history
2023Patents assigned to CHILDRENS MEDICAL CENTER (1)· patent assignee history
2024Patents assigned to HARVARD COLLEGE (1)· patent assignee history
2024Patents assigned to INTELLIA THERAPEUTICS INC (1)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| DANA FARBER CANCER INST INC | 5 | 2022–2024 |
| NOVARTIS AG | 3 | 2022–2025 |
| CHILDRENS MEDICAL CENTER | 1 | 2023 |
| HARVARD COLLEGE | 1 | 2024 |
| INTELLIA THERAPEUTICS INC | 1 | 2024 |
Locations
| Location | Patents | Span |
|---|---|---|
| US | 7 | 2022–2025 |